Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- UPMC Western Maryland — Cumberland, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Kaiser Permanente-Woodlawn Medical Center — Baltimore, Maryland
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Maryland: - UM Upper Chesapeake Medical Center — Bel Air, Maryland
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- University of Maryland Shore Medical Center at Easton — Easton, Maryland
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Maryland: - Sinai Hospital of Baltimore, Inc. — Baltimore, Maryland
- St. Agnes Hospital — Baltimore, Maryland
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- American Oncology Partners of Maryland, PA — Bethesda, Maryland
- James M Stockman Cancer Institute — Frederick, Maryland
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Maryland: - Holy Cross Hospital ( Site 0069) — Silver Spring, Maryland
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Maryland: - The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A. — Bethesda, Maryland
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Maryland: - Local Institution - 1035 — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Maryland: - Research Site — Bethesda, Maryland
- Research Site — Towson, Maryland
Phase 3 Recruiting Industry
This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T…
Sponsor: Daiichi Sankyo
NCT ID: NCT07683754
Sites in Maryland: - Maryland Oncology Hematology, P.A. — Columbia, Maryland
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Maryland: - USOR Maryland Oncology Hematology — Rockville, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Maryland: - Holy Cross Hospital — Silver Spring, Maryland
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Maryland: - The John Hopkins Hospital — Baltimore, Maryland
- Maryland Oncology Hematology- Columbia — Rockville, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in Maryland: - Research Site — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06245889
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 2 Recruiting NIH
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These ce…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01174121
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Maryland: - United Theranostics — Glen Burnie, Maryland
Phase 1 Recruiting Academic/Other
This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling…
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT05029999
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Maryland: - Mercy Medical Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
- MedStar Southern Maryland Hospital Center — Clinton, Maryland
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Christiana Care - Union Hospital — Elkton, Maryland
- UM Baltimore Washington Medical Center/Tate Cancer Center — Glen Burnie, Maryland
- UM Saint Joseph Medical Center — Towson, Maryland
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Maryland: - Massive Bio SYNERGY-AI site — Baltimore, Maryland
- Massive Bio SYNERGY-AI site — Bethesda, Maryland
- Massive Bio SYNERGY-AI site — Silver Spring, Maryland
- Massive Bio SYNERGY-AI site — Towson, Maryland
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Maryland: - Northwest Hospital — Randallstown, Maryland
- William E. Kahlert Regional Cancer Center — Westminster, Maryland
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in Maryland: - Research Site — Frederick, Maryland
- Research Site — Glenn Dale, Maryland
Recruiting Industry
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-u…
Sponsor: Elephas
NCT ID: NCT07327489
Sites in Maryland: - Frederick Health Hospital — Frederick, Maryland